The Ebola vaccine trial in Africa shows promising initial results, according to a report in the Lancet medical journal.
Scientists say it is a crucial step as other vaccines have shown lower levels of protection in African populations.
Tests involving Ugandan and American volunteers reveal the vaccine is so far safe and generates an immune response in both populations.
It provides reassurance for other trials currently underway, they say.
The Ebola virus has killed more than 6,900 people in the worst-affected countries of Sierra Leone, Liberia and Guinea.
No proven vaccine exists to prevent people from getting the disease, though several trials are underway.
The aim of a successful vaccine is to train the immune systems of healthy people to produce antibodies – proteins capable of fighting off any future infections.
Researchers from the National Institutes of Health tested this experimental vaccine on healthy adults in Uganda, having first trialed it in the US.
Dr. Julie Ledgerwood, the lead researcher, said: “This is the first study to show comparable safety and immune response of an experimental Ebola vaccine in an African population.
“This is particularly encouraging because those at greatest risk of Ebola live primarily in Africa and diminished vaccine protection in African populations has been seen for other diseases.”
According to the study some 57% of people in Uganda who received the Ebola vaccine alone developed antibodies against Ebola in their blood.
However, further tests would be needed to see if the antibodies are strong enough and long-lasting enough to provide adequate protection against the disease.
